| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | MK-2206 | CTRPv2 | pan-cancer | AAC | 0.013 | 0.7 |
| mRNA | BRD-K02251932 | CTRPv2 | pan-cancer | AAC | 0.014 | 0.7 |
| mRNA | piperlongumine | CTRPv2 | pan-cancer | AAC | 0.011 | 0.7 |
| mRNA | Methotrexate | CTRPv2 | pan-cancer | AAC | 0.013 | 0.7 |
| mRNA | Docetaxel | CTRPv2 | pan-cancer | AAC | 0.017 | 0.7 |
| mRNA | Bryostatin 1 | FIMM | pan-cancer | AAC | -0.094 | 0.7 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.013 | 0.7 |
| mRNA | lenalidomide | GDSC1000 | pan-cancer | AAC | -0.013 | 0.7 |
| mRNA | VU0155056 | CTRPv2 | pan-cancer | AAC | -0.013 | 0.7 |
| mRNA | SZ4TA2 | CTRPv2 | pan-cancer | AAC | -0.019 | 0.7 |